Cortexyme (CRTX) Competitors $1.78 +0.02 (+1.14%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesTrends CRTX vs. OMCL, MDRX, HSTM, FATE, LXEO, TNYA, SOPH, MOLN, INBX, and CRDFShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), Veradigm (MDRX), HealthStream (HSTM), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), Molecular Partners (MOLN), Inhibrx (INBX), and Cardiff Oncology (CRDF). Cortexyme vs. Omnicell Veradigm HealthStream Fate Therapeutics Lexeo Therapeutics Tenaya Therapeutics SOPHiA GENETICS Molecular Partners Inhibrx Cardiff Oncology Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Do analysts rate CRTX or OMCL? Omnicell has a consensus price target of $52.00, indicating a potential upside of 15.61%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omnicell 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility & risk, CRTX or OMCL? Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Which has higher valuation & earnings, CRTX or OMCL? Omnicell has higher revenue and earnings than Cortexyme. Omnicell is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.59Omnicell$1.06B1.96-$20.37M-$0.39-115.33 Does the MarketBeat Community believe in CRTX or OMCL? Omnicell received 345 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 67.07% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote. CompanyUnderperformOutperformCortexymeOutperform Votes15464.44% Underperform Votes8535.56% OmnicellOutperform Votes49967.07% Underperform Votes24532.93% Is CRTX or OMCL more profitable? Cortexyme has a net margin of 0.00% compared to Omnicell's net margin of -1.66%. Omnicell's return on equity of 2.55% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Omnicell -1.66%2.55%1.35% Do insiders and institutionals believe in CRTX or OMCL? 63.2% of Cortexyme shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 27.9% of Cortexyme shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer CRTX or OMCL? In the previous week, Cortexyme had 1 more articles in the media than Omnicell. MarketBeat recorded 1 mentions for Cortexyme and 0 mentions for Omnicell. Omnicell's average media sentiment score of 1.24 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Overall Sentiment Cortexyme Neutral Omnicell Positive SummaryOmnicell beats Cortexyme on 12 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.07M$2.94B$5.07B$9.08BDividend YieldN/A1.90%4.87%4.21%P/E Ratio-0.5945.9499.0517.15Price / SalesN/A411.851,121.17116.80Price / CashN/A182.1041.5237.88Price / Book0.443.894.754.78Net Income-$89.94M-$42.21M$119.33M$225.60M7 Day Performance-13.30%-2.14%-1.86%-1.23%1 Month Performance-15.38%4.21%11.40%3.07%1 Year Performance58.56%18.39%30.26%16.48% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.78+1.1%N/A+58.6%$58.79MN/A-0.6055News CoverageOMCLOmnicell2.9215 of 5 stars$45.39-1.3%$52.00+14.6%+18.6%$2.10B$1.15B0.003,650Positive NewsMDRXVeradigm2.24 of 5 stars$9.75-2.5%$11.75+20.5%-3.7%$1.05B$1.53B0.008,000Analyst ForecastHSTMHealthStream4.0304 of 5 stars$32.47+0.4%$31.50-3.0%+19.5%$987.58M$287.99M49.751,092FATEFate Therapeutics3.5264 of 5 stars$2.05+11.7%$6.75+230.1%-45.1%$232.91M$13.45M-1.22550LXEOLexeo Therapeutics2.7972 of 5 stars$7.00+1.7%$23.80+240.0%-54.8%$231.46M$650,000.00-2.1858News CoverageGap DownTNYATenaya Therapeutics3.8995 of 5 stars$2.85+3.6%$17.33+508.2%-33.7%$225.78MN/A-1.91110Analyst ForecastNews CoverageSOPHSOPHiA GENETICS2.4636 of 5 stars$3.33+1.5%$6.50+95.2%-25.9%$217.72M$62.37M-3.01520Analyst ForecastNews CoveragePositive NewsMOLNMolecular Partners0.3459 of 5 stars$5.35-1.5%N/A+17.7%$215.80M$6.00M-2.53180News CoverageINBXInhibrx1.483 of 5 stars$14.59-0.2%N/A-49.7%$211.21M$1.57M0.00166CRDFCardiff Oncology2.0227 of 5 stars$4.07+3.8%$10.33+153.9%+195.8%$208.10M$490,000.00-4.1720 Related Companies and Tools Related Companies Omnicell Alternatives Veradigm Alternatives HealthStream Alternatives Fate Therapeutics Alternatives Lexeo Therapeutics Alternatives Tenaya Therapeutics Alternatives SOPHiA GENETICS Alternatives Molecular Partners Alternatives Inhibrx Alternatives Cardiff Oncology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
